biostudies-literatureHoyhtya MHelsinki UniversityHelsinki University HospitalPediatric Research Foundation116-124https://www.ebi.ac.uk/biostudies/studies/S-EPMC9825283biostudies-literatureUnknown29(1)<h4>Background</h4>The role of intestinal microbiota in inflammatory bowel diseases is intensively researched. Pediatric studies on the relation between microbiota and treatment response are sparse. We aimed to determine whether absolute abundances of gut microbes characterize the response to infliximab induction in pediatric inflammatory bowel disease.<h4>Methods</h4>We recruited pediatric patients with inflammatory bowel disease introduced to infliximab at Children's Hospital, University of Helsinki. Stool samples were collected at 0, 2, and 6 weeks for microbiota and calprotectin analyses. We defined treatment response as fecal calprotectin value <100 µg/g at week 6. Intestinal microbiota were analyzed by 16S ribosomal RNA gene amplicon sequencing using the Illumina MiSeq platform. We aInflammatory bowel diseasesQuantitative Fecal Microbiota Profiles Relate to Therapy Response During Induction With Tumor Necrosis Factor α Antagonist Infliximab in Pediatric Inflammatory Bowel Disease.PMC9825283024.002.002de Vos WMNissila EKolho KLDikareva EHoyhtya MKorpela KNikkonen AJunkkari SSaqib SSalonen AfalseQuantitative Fecal Microbiota Profiles Relate to Therapy Response During Induction With Tumor Necrosis Factor α Antagonist Infliximab in Pediatric Inflammatory Bowel Disease.<h4>Background</h4>The role of intestinal microbiota in inflammatory bowel diseases is intensively researched. Pediatric studies on the relation between microbiota and treatment response are sparse. We aimed to determine whether absolute abundances of gut microbes characterize the response to infliximab induction in pediatric inflammatory bowel disease.<h4>Methods</h4>We recruited pediatric patients with inflammatory bowel disease introduced to infliximab at Children's Hospital, University of Helsinki. Stool samples were collected at 0, 2, and 6 weeks for microbiota and calprotectin analyses. We defined treatment response as fecal calprotectin value <100 µg/g at week 6. Intestinal microbiota were analyzed by 16S ribosomal RNA gene amplicon sequencing using the Illumina MiSeq platform. We a2023-01-01T00:00:00Z2023 Jan2026-04-08T16:07:42.239Z2025-04-04T07:22:45.161ZS-EPMC98252833604041210.1093/ibd/izac182